Merck's Volume Plunges to 121st as $970M Traded Down 53.6% from Prior Session

Merck (MRK) closed at a 1.36% decline on September 22, 2025, with a trading volume of $0.97 billion, marking a 53.64% drop from the previous day's activity. The pharmaceutical giant ranked 121st in trading volume among listed stocks, reflecting a significant reduction in market participation during the session. The move follows mixed signals from regulatory updates and strategic shifts within the biopharma sector, which have historically influenced investor sentiment toward large-cap healthcare plays.

Recent developments highlighted Merck’s ongoing restructuring efforts, including the consolidation of R&D operations and a renewed focus on oncology and infectious disease pipelines. Analysts noted that while these strategic pivots aim to streamline costs, they also introduce short-term uncertainties regarding capital allocation and long-term growth visibility. Additionally, the company’s recent partnership negotiations with biotech firms have sparked speculation about potential inorganic growth avenues, though no concrete agreements were disclosed in the latest filings.

To build an accurate back-test we need to nail down a few practical details, because the implementation depends on them: 1. Universe • Are we looking at all U.S. common stocks (≈ 6 000 names) or a narrower universe (e.g. Russell 3000 constituents, S&P 500, Nasdaq-100, etc.)? • Do ADRs, ETFs or OTC securities need to be excluded? 2. “Top 500 by trading volume” • Should the ranking be based on share volume or on dollar turnover (volume × price)? • Ranking is performed at the end of each trading day, correct? 3. Trade execution convention • Buy at next day’s open and liquidate at that day’s close (standard one-day holding test)? • Equal-weight across the 500 names each day? 4. Transaction costs / slippage • Is it acceptable to ignore these, or would you like us to apply a flat cost (e.g. 2 bps per side)? Once the above points are clarified, I can generate the data-retrieval plan and run the systematic back-test for the period 2022-01-01 to the present.